Pfizer and AstraZeneca Strike Global Agreement for OTC Version of Nexium®

By Heather Cartwright

Pharma Deals Review: Vol 2012 Issue 8 (Table of Contents)

Published: 20 Aug-2012

DOI: 10.3833/pdr.v2012.i8.1791     ISSN: 1756-7874

Section: Distribution & Marketing

Fulltext:

Abstract

Pfizer has gained global rights to market an OTC version of AstraZeneca's blockbuster heartburn drug Nexium® (esomeprazole magnesium) for US$250 M upfront plus milestones and royalties...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details